Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (338) 338
index medicus (327) 327
male (193) 193
female (174) 174
heterocyclic compounds, 3-ring - therapeutic use (154) 154
hiv infections - drug therapy (143) 143
adult (140) 140
heterocyclic compounds, 3-ring - adverse effects (140) 140
heterocyclic compounds, 3-ring - administration & dosage (129) 129
middle aged (126) 126
heterocyclic compounds, 3-ring - pharmacology (116) 116
pharmacology & pharmacy (96) 96
animals (84) 84
raltegravir (80) 80
double-blind (79) 79
infectious diseases (79) 79
treatment outcome (79) 79
dolutegravir (74) 74
aged (70) 70
simeprevir (64) 64
drug therapy, combination (63) 63
heterocyclic compounds, 3-ring - pharmacokinetics (63) 63
drug therapy (61) 61
hiv (56) 56
once-daily dolutegravir (56) 56
analysis (54) 54
hiv integrase inhibitors - therapeutic use (52) 52
immunology (52) 52
therapy (51) 51
hiv integrase inhibitors - adverse effects (50) 50
mice (49) 49
young adult (49) 49
antiviral agents - therapeutic use (48) 48
sulfonamides - therapeutic use (46) 46
pharmacokinetics (45) 45
hepatitis c, chronic - drug therapy (44) 44
antiretroviral-naive adults (43) 43
clinical trials (43) 43
hiv infections - virology (43) 43
abridged index medicus (42) 42
drug interactions (42) 42
hiv infection (42) 42
hiv integrase inhibitors - administration & dosage (40) 40
hiv-1 - drug effects (40) 40
antiviral agents (39) 39
human immunodeficiency virus--hiv (38) 38
adolescent (37) 37
anti-hiv agents - therapeutic use (37) 37
infection (37) 37
oncology (37) 37
research (37) 37
health aspects (36) 36
hepacivirus - genetics (36) 36
safety (36) 36
care and treatment (35) 35
anti-hiv agents - adverse effects (34) 34
aids/hiv (33) 33
anti-hiv agents - administration & dosage (33) 33
antiretroviral therapy (33) 33
drug resistance, viral (33) 33
article (32) 32
drug administration schedule (32) 32
sulfonamides - adverse effects (32) 32
viral load (32) 32
antiretroviral drugs (31) 31
gastroenterology & hepatology (31) 31
hepatitis c virus (31) 31
hiv integrase inhibitors - pharmacokinetics (31) 31
sofosbuvir (31) 31
dose-response relationship, drug (30) 30
drug combinations (30) 30
genotype (30) 30
ribavirin - therapeutic use (30) 30
hepatitis c (29) 29
rna, viral - blood (29) 29
uridine monophosphate - analogs & derivatives (29) 29
hiv-1 infection (28) 28
microbiology (28) 28
hepacivirus - drug effects (27) 27
proto-oncogene proteins c-akt - antagonists & inhibitors (27) 27
resistance (27) 27
virology (27) 27
cancer (26) 26
clinical trials as topic (26) 26
double-blind method (26) 26
hiv integrase inhibitors - pharmacology (26) 26
hiv-1 (26) 26
dosage and administration (25) 25
heterocyclic compounds, 3-ring - chemistry (25) 25
integrase inhibitor (25) 25
interferon-alpha - therapeutic use (25) 25
medicine, general & internal (25) 25
toxicology (25) 25
efficacy (24) 24
mutation (24) 24
patients (24) 24
heterocyclic compounds, 3-ring (23) 23
initial treatment (23) 23
integrase (23) 23
internal medicine (23) 23
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (389) 389
German (3) 3
Spanish (2) 2
French (1) 1
Hungarian (1) 1
Japanese (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
by Timothy A. Yap and Li Yan and Amita Patnaik and Ivy Fearen and David Olmos and Kyriakos Papadopoulos and Richard D. Baird and Liliana Delgado and Adekemi Taylor and Lisa Lupinacci and Ruth Riisnaes and Lorna L. Pope and Simon P. Heaton and George Thomas and Michelle D. Garrett and Daniel M. Sullivan and Johann S. de Bono and Anthony W. Tolcher
Journal of Clinical Oncology, ISSN 0732-183X, 12/2011, Volume 29, Issue 35, pp. 4688 - 4695
Purpose AKT signaling is frequently deregulated in human cancers. MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in... 
EVALUATE | PI3K | EFFICACY | ONCOLOGY | PATHWAY | IN-VIVO | GUIDELINES | TOXICITY | HUMAN CANCER | Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Humans | Middle Aged | Neoplasms - enzymology | Male | Protein Kinase Inhibitors - adverse effects | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Aged, 80 and over | Adult | Female | Aged | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Neoplasms - pathology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Adverse events of raltegravir and dolutegravir
by Elzi, Luigia and Erb, Stefan and Furrer, Hansjakob and Cavassini, Matthias and Calmy, Alexandra and Vernazza, Pietro and Günthard, Huldrych and Bernasconi, Enos and Battegay, Manuel and Aubert, V and Battegay, M and Bernasconi, E and Böni, J and Braun, D.L and Bucher, H.C and Calmy, A and Cavassini, M and Ciuffi, A and Dollenmaier, G and Egger, M and Elzi, L and Fehr, J and Fellay, J and Furrer, H and Fux, C.A and Günthard, H.F and Haerry, D and Hasse, B and Hirsch, H.H and Hoffmann, M and Hösli, I and Kahlert, C and Kaiser, L and Keiser, O and Klimkait, T and Kouyos, R.D and Kovari, H and Ledergerber, B and Martinetti, G and Martinez De Tejada, B and Marzolini, C and Metzner, K.J and Müller, N and Nicca, D and Pantaleo, G and Paioni, P and Rauch, A and Rudin, C and Scherrer, A.U and Schmid, P and Speck, R and Stöckle, M and Tarr, P and Trkola, A and Vernazza, P and Wandeler, G and Weber, R and Yerly, S and Swiss HIV Cohort Study Grp and Swiss HIV Cohort Study Group
AIDS, ISSN 0269-9370, 08/2017, Volume 31, Issue 13, pp. 1853 - 1858
Objective: To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Design: Prospective... 
toxicity | raltegravir | dolutegravir | HIV | neuropsychiatric adverse events | INFECTIOUS DISEASES | VIROLOGY | ONCE-DAILY DOLUTEGRAVIR | IMMUNOLOGY | ANTIRETROVIRAL-NAIVE ADULTS | Raltegravir Potassium - adverse effects | Mental Disorders - epidemiology | Prospective Studies | Mental Disorders - chemically induced | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Male | Withholding Treatment | Switzerland | Drug-Related Side Effects and Adverse Reactions - epidemiology | Anti-HIV Agents - administration & dosage | Young Adult | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adolescent | Aged, 80 and over | Adult | Female | HIV Infections - drug therapy | Aged | Index Medicus | AIDS/HIV | Clinical Science | Concise Communications
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study
by Fried, Michael W and Buti, Maria and Dore, Gregory J and Flisiak, Robert and Ferenci, Peter and Jacobson, Ira and Marcellin, Patrick and Manns, Michael and Nikitin, Igor and Poordad, Fred and Sherman, Morris and Zeuzem, Stefan and Scott, Jane and Gilles, Leen and Lenz, Oliver and Peeters, Monika and Sekar, Vanitha and Smedt, Goedele and Beumont‐Mauviel, Maria
Hepatology, ISSN 0270-9139, 12/2013, Volume 58, Issue 6, pp. 1918 - 1929
The phase IIb, double‐blind, placebo‐controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered... 
PROTEASE INHIBITOR | ALPHA-2A | GENETIC-VARIATION | IL28B | VIRUS-INFECTION | TELAPREVIR | THERAPY | ANTIVIRAL ACTIVITY | GASTROENTEROLOGY & HEPATOLOGY | GENOME-WIDE ASSOCIATION | DECLINE | Simeprevir | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Ribavirin - administration & dosage | Adult | Female | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Interferon-alpha - adverse effects | Viral Load - drug effects | Sulfonamides - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
by Joseph J. Eron and Bonaventura Clotet and Jacques Durant and Christine Katlama and Princy Kumar and Adriano Lazzarin and Isabelle Poizot-Martin and Gary Richmond and Vincent Soriano and Mounir Ait-Khaled and Tamio Fujiwara and Jenny Huang and Sherene Min and Cindy Vavro and Jane Yeo and VIKING Study Grp and VIKING Study Group and for the VIKING Study Group
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2013, Volume 207, Issue 5, pp. 740 - 748
Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir... 
MAJOR ARTICLES AND BRIEF REPORTS | S/GSK1349572 | DTG | integrase inhibitor | Dolutegravir | raltegravir resistance | TRIAL | INFECTIOUS DISEASES | TREATMENT-NAIVE | ELVITEGRAVIR | COMBINATION THERAPY | MICROBIOLOGY | IMMUNOLOGY | Anti-HIV Agents - pharmacology | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | RNA, Viral - blood | Viral Load | Anti-HIV Agents - administration & dosage | Young Adult | HIV-1 - isolation & purification | Pyrrolidinones - pharmacology | Adult | Female | Antiretroviral Therapy, Highly Active - methods | Raltegravir Potassium | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Treatment Outcome | Plasma - virology | Pilot Projects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | HIV Infections - drug therapy | Aged | Major and Brief Reports | GSK1349572
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
by Clotet, Bonaventura, Dr and Feinberg, Judith, Prof and van Lunzen, Jan, Prof and Khuong-Josses, Marie-Aude, MD and Antinori, Andrea, MD and Dumitru, Irina, MD and Pokrovskiy, Vadim, Prof and Fehr, Jan, MD and Ortiz, Roberto, MD and Saag, Michael, Prof and Harris, Julia, MA and Brennan, Clare, DPT and Fujiwara, Tamio, PhD and Min, Sherene, MD and ING114915 Study Team
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9936, pp. 2222 - 2231
Summary Background Dolutegravir has been shown to be non-inferior to an integrase inhibitor and superior to a non-nucleoside reverse transcriptase inhibitor... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | RALTEGRAVIR | COBICISTAT | EMTRICITABINE | CO-FORMULATED ELVITEGRAVIR | NON-INFERIORITY TRIAL | DOUBLE-BLIND | VALIDATION | INITIAL TREATMENT | INTEGRASE INHIBITOR | HIV-1 | Darunavir | Drug Administration Schedule | Ritonavir - administration & dosage | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Anti-HIV Agents - administration & dosage | Young Adult | Creatinine - metabolism | Ritonavir - adverse effects | Analysis of Variance | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adolescent | Sulfonamides - adverse effects | Adult | Female | HIV Infections - drug therapy | Aged | Sulfonamides - administration & dosage | Serum Albumin - metabolism | Dosage and administration | Research | Drug therapy | Comparative analysis | HIV infection | Antiretroviral drugs | Mutation | Drug dosages | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
by Walmsley, Sharon L and Antela, Antonio and Clumeck, Nathan and Duiculescu, Dan and Eberhard, Andrea and Gutiérrez, Felix and Hocqueloux, Laurent and Maggiolo, Franco and Sandkovsky, Uriel and Granier, Catherine and Pappa, Keith and Wynne, Brian and Min, Sherene and Nichols, Garrett and SINGLE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 19, pp. 1807 - 1818
There has been remarkable improvement in primary antiretroviral therapy (ART) for human immunodeficiency virus type 1 infection over the past 15 years. The... 
MEDICINE, GENERAL & INTERNAL | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | EMTRICITABINE | EFAVIRENZ | NON-INFERIORITY TRIAL | CO-FORMULATED ELVITEGRAVIR | DOUBLE-BLIND | INITIAL TREATMENT | PHASE-3 | ANTIRETROVIRAL-NAIVE ADULTS | Anti-Retroviral Agents - therapeutic use | Double-Blind Method | Humans | Middle Aged | Anti-Retroviral Agents - adverse effects | Male | RNA, Viral - blood | HIV-1 - genetics | Lamivudine - adverse effects | Young Adult | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Lamivudine - therapeutic use | Aged, 80 and over | Adult | Female | HIV Infections - drug therapy | Aged | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | Research | HIV (Viruses) | Drug therapy | Abacavir | Integrase | Emtricitabine | Antiretroviral drugs | Lamivudine | Infections | Lymphocytes T | Ribonucleic acid--RNA | Efavirenz | Manuscripts | Dreams | CD4 antigen | Tenofovir | Sleep disorders | Antiretroviral agents | Human immunodeficiency virus--HIV | Anxiety | Mutation | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
by Min, Sherene and Sloan, Louis and Dejesus, Edwin and Hawkins, Trevor and McCurdy, Lewis and Song, Ivy and Stroder, Richard and Chen, Shuguang and Underwood, Mark and Fujiwara, Tamio and Piscitelli, Stephen and Lalezari, Jay
AIDS, ISSN 0269-9370, 09/2011, Volume 25, Issue 14, pp. 1737 - 1745
Objective: To evaluate the antiviral activity, safety, pharmacokinetics, and pharmacokinetics/pharmacodynamics of dolutegravir (DTG), a next-generation HIV... 
pharmacokinetics | dose response | antiretroviral therapy | pharmacodynamics | integrase inhibitor | ANTIRETROVIRAL-NAIVE | INFECTIOUS DISEASES | RESISTANT HIV-1 INFECTION | PHASE-II | IMMUNOLOGY | GS-9137 | INTEGRASE INHIBITOR RALTEGRAVIR | TREATMENT-NAIVE | THERAPY | VIROLOGY | Anti-HIV Agents - pharmacology | Double-Blind Method | Drug Administration Schedule | Area Under Curve | HIV-1 - drug effects | Heterocyclic Compounds, 3-Ring - pharmacology | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Dose-Response Relationship, Drug | Anti-HIV Agents - pharmacokinetics | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Heterocyclic Compounds, 3-Ring - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
by Cahn, Pedro, Dr and Pozniak, Anton L, MD and Mingrone, Horacio, MD and Shuldyakov, Andrey, MD and Brites, Carlos, MD and Andrade-Villanueva, Jaime F, MD and Richmond, Gary, MD and Buendia, Carlos Beltran, MD and Fourie, Jan, MD and Ramgopal, Moti, MD and Hagins, Debbie, MD and Felizarta, Franco, MD and Madruga, Jose, MD and Reuter, Tania, MD and Newman, Tamara, MD and Small, Catherine B, MD and Lombaard, John, MD and Grinsztejn, Beatriz, MD and Dorey, David, MMath and Underwood, Mark, PhD and Griffith, Sandy, PharmD and Min, Sherene, MD and Extended SAILING Study Team and extended SAILING Study Team
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9893, pp. 700 - 708
Summary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We... 
Internal Medicine | TRIAL | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | COBICISTAT | EMTRICITABINE | EFAVIRENZ | CO-FORMULATED ELVITEGRAVIR | CROSS-RESISTANCE | INITIAL TREATMENT | PHASE-II | INFECTION | HIV-1 | Pyrrolidinones - adverse effects | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Drug Resistance, Viral | Male | Treatment Outcome | HIV Integrase Inhibitors - administration & dosage | Viral Load | Pyrrolidinones - administration & dosage | HIV Integrase Inhibitors - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adult | Female | HIV Infections - drug therapy | RNA, Viral - metabolism | Raltegravir Potassium | Drug therapy | HIV infection | Research | Patient safety | Plasma | Mutation | Drug dosages | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
by Jacobson, Ira M, Prof and Dore, Gregory J, Prof and Foster, Graham R, Prof and Fried, Michael W, Prof and Radu, Monica, MD and Rafalsky, Vladimir V, Prof and Moroz, Larysa, Prof and Craxi, Antonio, Prof and Peeters, Monika, MSc and Lenz, Oliver, PhD and Ouwerkerk-Mahadevan, Sivi, PhD and De La Rosa, Guy, MD and Kalmeijer, Ronald, MD and Scott, Jane, PhD and Sinha, Rekha, PhD and Beumont-Mauviel, Maria, PhD
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Summary Background Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | IN-VITRO | IMPACT | TELAPREVIR | THERAPY | PROFILE | SAFETY | BOCEPREVIR | VIROLOGICAL RESPONSE | PEGINTERFERON | ONCE-DAILY TMC435 | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Ribavirin - administration & dosage | Sulfonamides - adverse effects | Adult | Female | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Methods | Analysis | Clinical trials | Genetic aspects | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Genotype & phenotype | Infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
by Forns, Xavier and Lawitz, Eric and Zeuzem, Stefan and Gane, Ed and Bronowicki, Jean Pierre and Andreone, Pietro and Horban, Andrzej and Brown, Ashley and Peeters, Monika and Lenz, Oliver and Ouwerkerk–Mahadevan, Sivi and Scott, Jane and De La Rosa, Guy and Kalmeijer, Ronald and Sinha, Rekha and Beumont–Mauviel, Maria
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir... 
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | ALPHA-2A | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | MANAGEMENT | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | BOCEPREVIR | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights